.st0{fill:#FFFFFF;}

The Week in Healthcare: Legal Trouble in Pharma and Poor Healthcare Systems Concern Sector 

 enero 25, 2022


El contenido del artículo

lawsuit-settlement-healthcare-NAFTA-law-negotiation-by-witwiccan-150x150.jpg

In a complex week for the healthcare sector, one report points to low physical activity in one out of every four individuals in the world and another report indicates that up to 5 million people die every year in low and middle-income countries due to problems in their healthcare systems.

Sanofi and Bayer are facing legal trouble, with the former finally settling a civil lawsuit for bribery and Bayer facing trouble from Monsanto’s lawsuits.

In local news, new NAFTA provisions may affect the health of Mexicans. Mexico Health Review launched its fourth edition in a summit that brought together the main industry players in the sector for a conversation of the main topics concerning the sector. To read a summary of the addressed topics click here.

National

NAFTA negotiations now include a provision that forbids governments from forcing food and beverage manufacturing to label the nutritional content of their products, complained Alianza por Salud Alimentaria.

“More than a third of the Mexican population is obese and another third is on the frontier of obesity,” said Yiannis Mallis, General Manager and Vice President of Novo Nordisk Mexico at the fourth edition of the Mexico Health Summit.

International

Thermo Fisher Scientific will acquire BD’s Advanced Bioprocessing Business to strengthen its value proposition for biologic drug manufacturers.

5 million deaths per year are caused by poor healthcare systems in low and middle-income countries, reports a study in The Lancet.

Researchers report that 27.9 percent of the world’s population does not perform sufficient physical activity.

Sanofi reached a civil agreement with the US Security and Exchanges Commission (SEC) to pay US$25 million in a bribery settlement.

Monsanto’s piling lawsuits, which now add up to 8,700, cause Bayer to cut its earnings forecast.

Admin


There are no reviews yet. Be the first one to write one.